According to the company’s price at the time of writing, it is currently valued at 7.202 on the stock exchange. This is 1.45 percent up from the close of trading yesterday as the company receives a boost following the Medicines and Healthcare products Regulatory Agency’s (MHRA) press conference on Wednesday. Amid the scepticism over the drug from EU officials, AstraZeneca’s price has plummeted over the last six months.
Indeed, due to criticism from EU leaders, the stock price fell to a low of 6,858 on February 27.
On Wednesday, the MHRA revealed blood cots were rare among the nearly 200 million people who have received the jab.
Although an alternative jab will be offered to under-30s, the MHRA claimed the drug was still suitable to be used in the UK.
June Raine, chief executive of the MHRA said: “The balance of benefits and known risks is still very favourable for the majority of people.
“The public’s safety is at the forefront of our minds.”
As of March 31, the MHRA received 79 reports of blood clotting in the UK following the use of the vaccine.
Of those cases, 19 died following a first dose of the AstraZeneca vaccine.
However, due to the 20.2 million doses of the drug which has been administered, the overall risk of blood clotting remains at four to one million who are at risk.